Journal of Urgent Care Medicine

GLP-1 Users May Have Higher Risk For Chronic Cough

Use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) may be associated with chronic cough, as published in JAMA Otolaryngology–Head & Neck Surgery. A large study of more than 2 million people with type 2 diabetes across 70 healthcare organizations suggests that adults prescribed a GLP-1RA had a 12% higher risk for developing a new cough persisting for more than 8 weeks, compared with people prescribed other medications, including dipeptidyl peptidase-4 (DPP-4) inhibitors, sodium-glucose cotransporter 2 (SGLT2) …

GLP-1 Scripts As High As 34% For Those With Diabetes And Obesity

From 2010 to 2024, prescriptions for glucagon-like peptide 1 receptor agonists (GLP-1RAs) increased substantially among individuals with type 2 diabetes (T2D) and obesity, according to a research letter in JAMA Network Open, which examined electronic medical records of more than 300 million Americans. Rates rose from 2.4% to 34.3% among individuals with both T2D and obesity; from 0.6% to 13.7% in those with T2D only; and 0.04% to 7.1% in those with obesity only. The …

Login to JUCM